News

Our Healthcare News

AxoGen, Inc. Receives David J. Gury Company of the Year Award from BioFlorida

ALACHUA, Florida (GLOBE NEWSWIRE)—AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, has received the BioFlorida David…  

Oct 18 2017

Grupo Biotoscana and EISAI Sign Licensing Agreement for Four Oncology & Neurology Products in LatAm

MONTEVIDEO, Uruguay and WOODCLIFF LAKE, New Jersey—GBT-Grupo Biotoscana (B3: GBIO33), a leading biopharmaceutical company in Latin America, today announced that it has entered into an…  

Oct 03 2017

Grupo Biotoscana Expands Partnership with Gilead Sciences in HCV in Brazil

Montevideo, Uruguay—GBT-Grupo Biotoscana (B3: GBIO33), a leading specialty pharmaceutical company in Latin America, today announced that it has expanded its partnership with Gilead Sciences (Nasdaq:…  

Aug 30 2017

AxoGen, Inc Reports 2017 Second Quarter Financial Results, Representing 46% Growth over Prior Year

ALACHUA, Fla., (GLOBE NEWSWIRE)—AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and…  

Aug 02 2017

Abiomed Announces Q1 FY 2018 Revenue of $132.5 Million, Up 29% Over Prior Year

DANVERS, Massachusetts—  Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today reported first quarter fiscal 2018 revenue of $132.5 million, an…  

Jul 27 2017

Grupo Biotoscana Raises $417 Million in Oversubscribed Brazil IPO

LONDON, United Kingdom—EW Healthcare Partners (“EWHP”), a global healthcare growth equity investor, announced that Grupo Biotoscana (“Biotoscana”), a Pan-Latin American specialty pharmaceutical company focused on…  

Jul 21 2017

Venus Concept Closes $38 Million Equity Financing to Support Continued Growth Opportunities

TORONTO, Canada—Venus Concept Ltd., a privately-held and innovative global aesthetic technology leader, today announced the closing of a $38 million equity investment. The equity investment…  

Jul 13 2017

EUSA Pharma Receives Positive CHMP Opinion for Tivozanib for First-Line Treatment

HEMEL HEMPSTEAD, England – – EUSA Pharma (EUSA), a specialty pharmaceutical company with a focus on oncology and oncology supportive care, today announced that the…  

Jun 23 2017

Endologix Provides an Update on the Nellix Endovascular Aneurysm Sealing System US Regulatory Status

IRVINE, California – Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that the Company met with the…  

May 17 2017



View Legacy Fund news >